The Russian pharmaceutical conglomerate “R-Pharm” has successfully registered the medication “Deltiba” (delamanid) in the Republic of Belarus to combat multidrug-resistant pulmonary tuberculosis. Combination regimens incorporating it have shown efficacy in treating both adult and pediatric patients suffering from resistant strains of tuberculosis.
Last year, the original drug developed by Otsuka Pharmaceutical from Japan (currently manufactured by R-Pharm) was granted registration in Russia. Deltiba was the inaugural drug to successfully navigate the newly instituted regulatory certification process established by the EAEU.
Dlamanid is classified as an essential medicine by both the World Health Organization and the Ministry of Health of the Russian Federation, and is included in their respective lists of Vital and Essential Drugs.
